Uncovering the Q-marker and potential mechanisms of Qishan Formula for lung cancer based on multi-technology

References

• Sung, H.; Ferlay, J.; Siegel, R. L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021, 71, 209–249. DOI: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Yoo, J. S.; Yang, H. C.; Lee, J. M.; Kim, M. S.; Park, E.-C.; Chung, S. H. The Association of Physical Function and Quality of Life on Physical Activity for Non-Small Cell Lung Cancer Survivors. Support. Care Cancer 2020, 28, 4847–4856. DOI: 10.1007/s00520-020-05302-6.
   PubMed Web of Science ®Google Scholar
• Granger, C. L.; McDonald, C. F.; Irving, L.; Clark, R. A.; Gough, K.; Murnane, A.; Mileshkin, L.; Krishnasamy, M.; Denehy, L. Low Physical Activity Levels and Functional Decline in Individuals with Lung Cancer. Lung Cancer 2014, 83, 292–299. DOI: 10.1016/j.lungcan.2013.11.014.
   PubMed Web of Science ®Google Scholar
• Khue, P. M.; Thom, V. T.; Minh, D. Q.; Quang, L. M.; Hoa, N. L. Depression and Anxiety as Key Factors Associated with Quality of Life among Lung Cancer Patients in Hai Phong, Vietnam. Front. Psychiatry 2019, 10, 352. DOI: 10.3389/fpsyt.2019.00352.
   PubMed Web of Science ®Google Scholar
• Mendoza, T. R.; Kehl, K. L.; Bamidele, O.; Williams, L. A.; Shi, Q.; Cleeland, C. S.; Simon, G. Assessment of Baseline Symptom Burden in Treatment-Naïve Patients with Lung Cancer: An Observational Study. Support. Care Cancer 2019, 27, 3439–3447. DOI: 10.1007/s00520-018-4632-0.
   PubMed Web of Science ®Google Scholar
• Sung, M. R.; Patel, M. V.; Djalalov, S.; Le, L. W.; Shepherd, F. A.; Burkes, R. L.; Feld, R.; Lin, S.; Tudor, R.; Leighl, N. B. Evolution of Symptom Burden of Advanced Lung Cancer over a Decade. Clin. Lung Cancer 2017, 18, 274–280. e6. DOI: 10.1016/j.cllc.2016.12.010.
   PubMed Web of Science ®Google Scholar
• Dang, Y.; Wang, R.; Qian, K.; Lu, J.; Zhang, H.; Zhang, Y. Clinical and Radiological Predictors of Epidermal Growth Factor Receptor Mutation in Nonsmall Cell Lung Cancer. J. Appl. Clin. Med. Phys. 2021, 22, 271–280. DOI: 10.1002/acm2.13107.
   PubMed Web of Science ®Google Scholar
• Mao, Y.; Yang, D.; He, J.; Krasna, M. J.. Epidemiology of Lung Cancer. Surg. Oncol. Clin. N Am. 2016, 25, 439–445. DOI: 10.1016/j.soc.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Sui, Y.; Chi, W.; Jiang, J. Effect of Qishan Capsule on PI3KAKt Signaling Pathway in Lung Cancer A549 Cells. Chin. Med. Pharm. 2018, 46, 22–27.
   Google Scholar
• Liu, C. X. Construction of Traceability System of Chinese Materia Medica Product Quality Based on Quality Marker of Chinese Materia Medica. Chin. Tradit. Herbal Drugs 2017, 48, 3669–3676.
   Google Scholar
• Liu, C. X. Quality Marker(Q-Marker) of Chinese Materia Medica: Improving Quality Standard and Quality Control Theory of CMM and Promoting Scientific Development of CMM Industry. Chin. Tradit. Herbal Drugs 2019, 50, 4517–4518.
   Google Scholar
• Shi, W.; Wu, Z.; Wu, J.; Jia, M.; Yang, C.; Feng, J.; Lou, Y.; Fan, G. A Comprehensive Quality Control Evaluation for Standard Decoction of Smilax Glabra Roxb Based on HPLC-MS-UV/CAD Methods Combined with Chemometrics Analysis and Network Pharmacology. Food Chem. 2023, 410, 135371. DOI: 10.1016/j.foodchem.2022.135371.
   PubMed Web of Science ®Google Scholar
• Han, T.; Zhang, L.; Tong, W.; Zhao, J.; Wang, W. Exploring the Interaction of Calycosin with Cyclin D1 Protein as a Regulator of Cell Cycle Progression in Lung Cancer Cells. Arab. J. Chem. 2022, 15, 103722. DOI: 10.1016/j.arabjc.2022.103722.
   Web of Science ®Google Scholar
• Deng, M.; Chen, H.; Long, J.; Song, J.; Xie, L.; Li, X. Calycosin: A Review of Its Pharmacological Effects and Application Prospects. Expert Rev. Anti. Infect. Ther. 2021, 19, 911–925. DOI: 10.1080/14787210.2021.1863145.
   PubMed Web of Science ®Google Scholar
• Hong, J.; Gwon, D.; Jang, C.-Y. Ginsenoside Rg1 Suppresses Cancer Cell Proliferation through Perturbing Mitotic Progression. J. Ginseng Res. 2022, 46, 481–488. DOI: 10.1016/j.jgr.2021.11.004.
   PubMed Web of Science ®Google Scholar
• Mohanan, P.; Subramaniyam, S.; Mathiyalagan, R.; Yang, D. C. Molecular Signaling of Ginsenosides Rb1, Rg1, and Rg3 and Their Mode of Actions. J. Ginseng Res. 2018, 42, 123–132.
   PubMed Web of Science ®Google Scholar
• Ma, L.; Mao, R.; Shen, K.; Zheng, Y.; Li, Y.; Liu, J.; Ni, L. Atractylenolide I-Mediated Notch Pathway Inhibition Attenuates Gastric Cancer Stem Cell Traits. Biochem. Bioph. Res. Co. 2014, 450, 353–359.
   PubMed Web of Science ®Google Scholar
• Zhou, W.; Wang, J.; Wu, Z.; Huang, C.; Lu, A.; Wang, Y. Systems Pharmacology Exploration of Botanic Drug Pairs Reveals the Mechanism for Treating Different Diseases. Sci. Rep. 2016, 6, 36985. DOI: 10.1038/srep36985.
   PubMed Web of Science ®Google Scholar
• Ai, H.; Wu, X.; Qi, M.; Zhang, L.; Hu, H.; Zhao, Q.; Zhao, J.; Liu, H. Study on the Mechanisms of Active Compounds in Traditional Chinese Medicine for the Treatment of Influenza Virus by Virtual Screening. Interdiscip. Sci. Comput. Life Sci. 2018, 10, 320–328.
   PubMed Web of Science ®Google Scholar
• Zhao, B.; Wang, Y.; Wang, Y.; Chen, W.; Zhou, L.; Liu, P. H.; Kong, Z.; Dai, C.; Wang, Y.; Ma, W. Efficacy and Safety of Therapies for EGFR-Mutant Non-Small Cell Lung Cancer with Brain Metastasis: An Evidence-Based Bayesian Network Pooled Study of Multivariable Survival Analyses. Aging 2020, 12, 14244–14270. DOI: 10.18632/aging.103455.
   PubMedGoogle Scholar
• Zou, Z.; Tao, T.; Li, H.; Zhu, X. mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Progress and Challenges. Cell Biosci. 2020, 10, 1–11. DOI: 10.1186/s13578-020-00396-1.
   PubMed Web of Science ®Google Scholar
• El-Mihi, K. A.; Kenawy, H. I.; El-Karef, A.; Elsherbiny, N. M.; Eissa, L. A. Naringin Attenuates Thioacetamide-Induced Liver Fibrosis in Rats through Modulation of the PI3K/Akt Pathway. Life Sci. 2017, 187, 50–57. DOI: 10.1016/j.lfs.2017.08.019.
   PubMed Web of Science ®Google Scholar
• Yan, S.; Zhang, B.; Feng, J.; Wu, H.; Duan, N.; Zhu, Y.; Zhao, Y.; Shen, S.; Zhang, K.; Wu, W.; Liu, N. FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway. Front. Pharmacol. 2021, 12, 764699. DOI: 10.3389/fphar.2021.764699.
   PubMed Web of Science ®Google Scholar